Yan Xiaoyang, Gao Hongwei
School of Life Science, Ludong University, Yantai, China.
Front Oncol. 2022 May 19;12:860159. doi: 10.3389/fonc.2022.860159. eCollection 2022.
In this paper, we selected Pt(en)Cl, Pt(dach)Cl, and Pt(bipy)Cl with gradually increasing ligands to explore the ligand effect on the properties of platinum(IV) anticancer drugs. The electronic structures and multiple drug properties of these three complexes were studied at the LSDA/SDD level using the density functional theory (DFT) method. By comparing the gap between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO), electron affinity, atomic charge population, and natural bond orbital (NBO), we found that the order of reducibility is Pt(bipy)Cl > Pt(en)Cl > Pt(dach)Cl. Our research can provide the theoretical basis for the development of anticancer drugs.
在本文中,我们选择了配体逐渐增多的Pt(en)Cl、Pt(dach)Cl和Pt(bipy)Cl,以探究配体对铂(IV)抗癌药物性质的影响。采用密度泛函理论(DFT)方法,在LSDA/SDD水平上研究了这三种配合物的电子结构和多种药物性质。通过比较最高占据分子轨道(HOMO)和最低未占据分子轨道(LUMO)之间的能隙、电子亲和能、原子电荷布居和自然键轨道(NBO),我们发现还原能力的顺序为Pt(bipy)Cl > Pt(en)Cl > Pt(dach)Cl。我们的研究可为抗癌药物的开发提供理论依据。